merged_alzheimers-treatment-kisunla-donanemab.txt
<question_number>1</question_number>
<answer>significant safety risks (brain swelling and bleeding)</answer>
<question_number>2</question_number>
<answer>may discourage patients from enrolling in trials of other potential treatments</answer>
<question_number>3</question_number>
<answer>no correlation between amyloid removal and clinical response in individual patients</answer>
<question_number>4</question_number>
<answer>raises greater safety concerns about Kisunla</answer>
<question_number>5</question_number>
<answer>patients can stop after amyloid cleared, reducing overall cost and inconvenience</answer>
<question_number>6</question_number>
<answer>could deter participation in other clinical trials</answer>
<question_number>7</question_number>
<answer>can be stopped after plaques cleared and is given monthly instead of every two weeks</answer>
<question_number>8</question_number>
<answer>amyloid</answer>
<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>
<question_number>10</question_number>
<answer>intermediate tau levels indicating earlier disease stage</answer>